These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 10900007)

  • 1. alpha -galactosylceramide-activated Valpha 14 natural killer T cells mediate protection against murine malaria.
    Gonzalez-Aseguinolaza G; de Oliveira C; Tomaska M; Hong S; Bruna-Romero O; Nakayama T; Taniguchi M; Bendelac A; Van Kaer L; Koezuka Y; Tsuji M
    Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8461-6. PubMed ID: 10900007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced gamma interferon production through activation of Valpha14(+) natural killer T cells by alpha-galactosylceramide in interleukin-18-deficient mice with systemic cryptococcosis.
    Kawakami K; Kinjo Y; Yara S; Uezu K; Koguchi Y; Tohyama M; Azuma M; Takeda K; Akira S; Saito A
    Infect Immun; 2001 Nov; 69(11):6643-50. PubMed ID: 11598033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-administration of α-GalCer analog and TLR4 agonist induces robust CD8(+) T-cell responses to PyCS protein and WT-1 antigen and activates memory-like effector NKT cells.
    Coelho-Dos-Reis JG; Huang J; Tsao T; Pereira FV; Funakoshi R; Nakajima H; Sugiyama H; Tsuji M
    Clin Immunol; 2016 Jul; 168():6-15. PubMed ID: 27132023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide.
    Hayakawa Y; Takeda K; Yagita H; Kakuta S; Iwakura Y; Van Kaer L; Saiki I; Okumura K
    Eur J Immunol; 2001 Jun; 31(6):1720-7. PubMed ID: 11385616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to malarial infection is achieved by the cooperation of NK1.1(+) and NK1.1(-) subsets of intermediate TCR cells which are constituents of innate immunity.
    Mannoor MK; Weerasinghe A; Halder RC; Reza S; Morshed M; Ariyasinghe A; Watanabe H; Sekikawa H; Abo T
    Cell Immunol; 2001 Aug; 211(2):96-104. PubMed ID: 11591113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines.
    Gonzalez-Aseguinolaza G; Van Kaer L; Bergmann CC; Wilson JM; Schmieg J; Kronenberg M; Nakayama T; Taniguchi M; Koezuka Y; Tsuji M
    J Exp Med; 2002 Mar; 195(5):617-24. PubMed ID: 11877484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multifactorial mechanism in the superior antimalarial activity of alpha-C-GalCer.
    Schmieg J; Yang G; Franck RW; Tsuji M
    J Biomed Biotechnol; 2010; 2010():283612. PubMed ID: 20069056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen.
    Hameg A; Apostolou I; Leite-De-Moraes M; Gombert JM; Garcia C; Koezuka Y; Bach JF; Herbelin A
    J Immunol; 2000 Nov; 165(9):4917-26. PubMed ID: 11046017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells.
    Kitamura H; Iwakabe K; Yahata T; Nishimura S; Ohta A; Ohmi Y; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nishimura T
    J Exp Med; 1999 Apr; 189(7):1121-8. PubMed ID: 10190903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel function of Valpha14+CD4+NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system.
    Tomura M; Yu WG; Ahn HJ; Yamashita M; Yang YF; Ono S; Hamaoka T; Kawano T; Taniguchi M; Koezuka Y; Fujiwara H
    J Immunol; 1999 Jul; 163(1):93-101. PubMed ID: 10384104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural killer T cell activation inhibits hepatitis B virus replication in vivo.
    Kakimi K; Guidotti LG; Koezuka Y; Chisari FV
    J Exp Med; 2000 Oct; 192(7):921-30. PubMed ID: 11015434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of hepatic NKT cells and subsequent liver injury following administration of alpha-galactosylceramide.
    Osman Y; Kawamura T; Naito T; Takeda K; Van Kaer L; Okumura K; Abo T
    Eur J Immunol; 2000 Jul; 30(7):1919-28. PubMed ID: 10940881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes.
    Sharif S; Arreaza GA; Zucker P; Mi QS; Sondhi J; Naidenko OV; Kronenberg M; Koezuka Y; Delovitch TL; Gombert JM; Leite-De-Moraes M; Gouarin C; Zhu R; Hameg A; Nakayama T; Taniguchi M; Lepault F; Lehuen A; Bach JF; Herbelin A
    Nat Med; 2001 Sep; 7(9):1057-62. PubMed ID: 11533711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes.
    Nishimura T; Kitamura H; Iwakabe K; Yahata T; Ohta A; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nakui M; Sekimoto M; Koda T
    Int Immunol; 2000 Jul; 12(7):987-94. PubMed ID: 10882410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of injury-induced suppression of T-cell immunity by the CD1d/NKT cell-specific ligand alpha-galactosylceramide.
    Tulley JM; Palmer JL; Gamelli RL; Faunce DE
    Shock; 2008 Feb; 29(2):269-77. PubMed ID: 17693934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells.
    Eberl G; MacDonald HR
    Eur J Immunol; 2000 Apr; 30(4):985-92. PubMed ID: 10760785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyporesponsiveness to natural killer T-cell ligand alpha-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxide.
    Yanagisawa K; Exley MA; Jiang X; Ohkochi N; Taniguchi M; Seino K
    Cancer Res; 2006 Dec; 66(23):11441-6. PubMed ID: 17145891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colocalization of a CD1d-Binding Glycolipid with a Radiation-Attenuated Sporozoite Vaccine in Lymph Node-Resident Dendritic Cells for a Robust Adjuvant Effect.
    Li X; Kawamura A; Andrews CD; Miller JL; Wu D; Tsao T; Zhang M; Oren D; Padte NN; Porcelli SA; Wong CH; Kappe SH; Ho DD; Tsuji M
    J Immunol; 2015 Sep; 195(6):2710-21. PubMed ID: 26254338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The complementarity determining region 2 of BV8S2 (V beta 8.2) contributes to antigen recognition by rat invariant NKT cell TCR.
    Pyz E; Naidenko O; Miyake S; Yamamura T; Berberich I; Cardell S; Kronenberg M; Herrmann T
    J Immunol; 2006 Jun; 176(12):7447-55. PubMed ID: 16751390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD1d-restricted NK T cells are dispensable for specific antibody responses and protective immunity against liver stage malaria infection in mice.
    Romero JF; Eberl G; MacDonald HR; Corradin G
    Parasite Immunol; 2001 May; 23(5):267-9. PubMed ID: 11309137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.